The World Health Organization estimates that up to 1.2 billion people globally, nearly one in six of the world’s population, are afflicted by neurological and/or mental health disorders. Misdiagnosis rates range from 19-69%, and mental health dropout rate of 40% is primarily due to treatment ineffectiveness.
It takes an average of 10 years (and millions of dollars) to bring new brain health-related therapies to market, which is tied to flawed protocols, arduous/delayed data analysis, and avoidable amendments in clinical research.
CereHealth™ (parent company) is a state-of-the-art, web-based brain imaging and data analytics company with a proprietary, scalable artificial intelligence (AI) platform focused on multivariable analysis of quantitative biomarkers for central nervous system (CNS) disorders.
At Our Core
CereHealth™ focuses on removing diagnostic bias and applying innovation to create a more precise understanding of brain-based disorders, enabling healthcare providers to make more-informed decisions regarding patient-specific treatments, and contract research organizations (CROs) to access interlocked capabilities that add value to the clinical trial process and workflows.